NCT01775423已完成1 期
A Phase I Clinical Study of BBI608 in Adult Patients With Advanced Malignancies
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 87
- 试验地点
- 3
- 主要终点
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
研究概览
简要总结
This is an open label, single arm, dose escalation study of BBI608 in patients with advanced malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
BBI608
Experimental
干预措施: BBI608 (Drug)
结局指标
主要结局
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
时间窗: Adverse events will be assessed at baseline, while the participant is taking BBI608, and for 30 days after stopping therapy. The average length of this duration is expected to be approximately 4 months.
Assessment of safety of BBI608 given in monotherapy to patients with advanced malignancies by reporting of adverse events and serious adverse events
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic MalignanciesHematologic MalignancyNCT02352558Sumitomo Pharma America, Inc.15
已完成
1 期
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced MalignanciesCancerNCT01325441Sumitomo Pharma America, Inc.565
已完成
1 期
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular CarcinomaHepatocellular CarcinomaNCT02279719Sumitomo Pharma America, Inc.97
已完成
1 期
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic CancerMetastatic Pancreatic AdenocarcinomaNCT02231723Sumitomo Pharma America, Inc.139
已完成
1 期
A Study of BBI503 in Adult Patients With Advanced Solid TumorsCancer, Advanced Solid TumorsNCT01781455Sumitomo Pharma America, Inc.311